Remicade infliximab regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending 3 mAbs against tumor necrosis factor (TNF) alpha to treat moderately to severely active ulcerative

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE